Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management

J Opioid Manag. 2019 Mar/Apr;15(2):147-158. doi: 10.5055/jom.2019.0496.

Abstract

Transdermal buprenorphine (TDB) has demonstrated effectiveness in treating a range of chronic pain conditions, including cancer pain, nociceptive pain, and neuropathic pain and has a favorable safety profile. Worldwide, clinical experience of its use is relatively limited. There is considerable misunderstanding about the pharmacology, mechanism of action, and safety of buprenorphine. There is also limited guidance on the appropriate use of TDB for chronic pain management. This article presents an overview of TDB and also provides practical recommendations for its use as part of a multifaceted strategy in chronic cancer and non-cancer pain.

MeSH terms

  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / therapeutic use
  • Buprenorphine / administration & dosage*
  • Buprenorphine / therapeutic use
  • Chronic Pain* / drug therapy
  • Chronic Pain* / etiology
  • Humans
  • Neoplasms / complications*
  • Pain Management
  • Pain Measurement
  • Transdermal Patch

Substances

  • Analgesics, Opioid
  • Buprenorphine